Humacyte (HUMA) Other Non-Current Assets (2020 - 2026)
Humacyte (HUMA) posted quarterly Other Non-Current Assets of $209000.0 for Q1 2026, down 99.58% year-over-year from $50.2 million in Q1 2025, and little changed quarter-over-quarter from $209000.0 in Q4 2025.
Humacyte (HUMA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Other Non-Current Assets for 7 consecutive years, with $209000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 99.58% year-over-year to $209000.0; the TTM figure through Mar 2026 stood at $209000.0 (down 99.58% YoY), while the FY2025 annual figure was $209000.0, down 83.29% from the prior year.
- Other Non-Current Assets steadied at $209000.0 in Q1 2026 per HUMA's latest filing, from $209000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $50.2 million in Q1 2025 and bottomed at $209000.0 in Q4 2023.
- Historically, Other Non-Current Assets has averaged $4.8 million across 5 years, with a median of $821500.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets soared 5963.89% — and 2026, when it slumped 99.58%.
- Humacyte's Other Non-Current Assets stood at $682000.0 in 2022, then tumbled by 69.35% to $209000.0 in 2023, then soared by 498.56% to $1.3 million in 2024, then slumped by 83.29% to $209000.0 in 2025, then changed by 0.0% to $209000.0 in 2026.
- Business Quant data shows HUMA's Other Non-Current Assets at $209000.0 in Q1 2026, $209000.0 in Q4 2025, and $209000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 62.96 Mn |
| 10 | Humacyte | 162.29 Mn | 162.29 Mn | -825,000.00 | 672,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 672,000.00 |
| Mar 31, 2026 | 209,000.00 |
| Dec 31, 2025 | 209,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 50.21 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 815,000.00 |
| Mar 31, 2024 | 828,000.00 |
| Dec 31, 2023 | 209,000.00 |
| Sep 30, 2023 | 855,000.00 |
| Dec 31, 2022 | 682,000.00 |
| Jun 30, 2021 | 15,397.00 |
| Dec 31, 2020 | 28,570.00 |